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ABSTRACT 
 
 
The possibility of an incident involving radiation exposure is at the forefront of 
public attention in the current global environment.  With a greater number of entities 
possessing nuclear weapons and increased demand for nuclear power, the concern for 
uncontained exposure to radiation is increasing.  In light of these developments, the need 
for treatments that may be easily stored and administered to large numbers of people who 
have been exposed to high doses of total body irradiation (TBI) is more urgent than ever 
before. 
 
Our goal was to identify and develop novel, drug-like small molecules that would 
exhibit radiomitigating activity for use in Acute Radiation Syndrome (ARS).  Hot water 
extracts of Cat’s Claw containing quinic acid have been shown to possess activity in 
increasing circulating white blood cells as well as promoting DNA repair.  Our group 
previously synthesized and evaluated a series of quinic acid derivatives.  Quinic acid 
derivative KZ-41 was identified and described as highly water soluble and orally 
available.  We have, therefore, identified a novel quinic acid derivative, KZ-41, as our 
initial lead molecule for evaluation, characterization, and development in the setting of 
ARS. 
 
Initial efficacy was tested in vivo by evaluating the impact KZ-41 had on the 
primary endpoint of mortality in lethally irradiated C57BL/6 mice 30 days after exposure.  
To investigate the potential mechanisms related to the enhanced survival following TBI, 
we investigated the effect of KZ-41 on parameters important to initial wound healing.  
We developed an imaging model to specifically investigate the effect of KZ-41 on 
clotting following TBI and vascular injury.  This model also allowed us to gain insight 
into “combined injury” which is also of critical importance when discussing the “real-
life” implications of ARS.  . 
 
To further evaluate mechanisms of effect, we developed an in vitro model using 
human monocytes (U937) cells.  Using the in vitro model developed, we characterized 
the effect KZ-41 had on intrinsic and extrinsic apoptotic cell death, focusing on the 
impact in the “bystander effect” model.  We also utilized the in vitro model to identify 
potential more potent analogues and next-generation compounds.  Initial pre-clinical 
pharmacokinetic characterization of a next-generation compound was also conducted. 
 
We have shown KZ-41 to be effective in improving survival of lethally irradiated 
mice, enhancing the critical wound healing events of initial thrombus formation, and in 
restoring vascular flow in combined injury.  In an in vitro bystander effect model, KZ-41 
can mitigate apoptosis when administered after the radiation event.  Initial identification 
and pharmacokinetic characterization of a potent next-generation compound for use in 
ARS is also described herein.  
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CHAPTER 1.  INTRODUCTION 
 
 
ACUTE RADIATION SYNDROME 
 
There is growing concern that the potential for nuclear attack is increasing.  Small 
scale attacks could involve hundreds to thousands of people exposed to total body 
irradiation (TBI) [1].  Acute radiation syndrome (ARS) results from radiation exposures 
greater than 1 Gy, to a significant portion of the body delivered at a relatively high dose 
rate.  Such radiation exposure can be from a nuclear accident (e.g., Chernobyl), from a 
military event (e.g., Hiroshima and Nagasaki), or through a terrorist incident.  ARS 
encompasses overlapping syndromes including hematopoietic (Hem-ARS), 
gastrointestinal, and neurological syndromes (Figure 1-1).  Victims whose TBI dose 
ranges from 2-6 Gy, known as the hematopoietic syndrome, will be most likely to be 
saved with treatment, and it is estimated that nearly all persons exposed to doses greater 
than 6 Gy will die within 30 days of exposure if not treated [2]. 
 
 
Hematopoietic Syndrome 
 
Hematopoietic stem cells are extremely vulnerable to γ-irradiation whose damage 
is the cause of Hem-ARS which occurs at the lowest radiation doses and is observed with 
increasing severity proportional to radiation dose (Figure 1-2).  Symptoms of moderate 
Hem-ARS is due to exposure to levels of ionizing radiation greater than 1-2 Gray, and 
manifests as bone marrow damage (Figure 1-3) [3].  Severe Hem-ARS is seen at ionizing 
radiation doses from 4 Gy [2, 4].  It is estimated that without supportive care (antibiotics 
and transfusions), a radiation dose of approximately 3.5-4.5 Gy will result in death of 
50% of persons exposed within 60 days (LD50/60) [3, 5, 6].  While ARS can affect many 
organ systems (e.g., dermal, cardiovascular) primary causes of morbidity and mortality in 
Hem-ARS are related to pancytopenia.  Death resulting from sepsis results from a 
decrease in innate immunity, both the numbers of circulating leukocytes and possibly the 
function [7, 8].  Hemorrhage associated mortality can be correlated with a significant 
decrease in circulating platelet levels and magakaryocyte precursors.  In the event of a 
nuclear accident or attack, there will be other injuries in addition to the radiation 
exposure.  It has been estimated that as many as 60-70% of ARS patients will have other 
injuries, and these patients will have a significantly lower LD50/60 
 
[5].  Additional injuries 
increase the probability of introduction of infection that a compromised hematopoietic 
system cannot combat.  Hematopoietic recovery must be attained or the patient will have 
no chance to recover from other injuries [9].  Therefore, hematopoietic support is 
essential at all radiation doses relevant to induce ARS.  
 
Gastrointestinal Syndrome 
 
Total body doses above approximately 8 Gy will involve serious injury to the 
gastrointestinal (GI) system, contributing to mortality [10].  Radiation doses from around 
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Figure 1-1 Radiation Doses Associated with Acute Radiation Syndrome. 
 
 
 
 
 
 
 
Figure 1-2  Differientation of Hematopoietic Progenitor Cells. 
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Figure 1-3  Effect of Radiation on Bone Marrow Cellularity
Normal bone marrow cellularity is dense as demonstrated by the panel on the left.  The 
panel on the right indicates reduced cellularity in the bone marrow after high dose 
irradiation. 
. 
 
 
 
 
 
  
Reduced After IR Normal 
 
4 
 
8-30 Gy elicit effects known as the GI syndrome.  Damage to intestinal mucosal stem  
cells is the hallmark of the GI syndrome.  The result of the damage to the intestine is 
decreased barrier function and abnormal absorption.  Clinical symptoms of GI-ARS 
include nausea, vomiting, and diarrhea in addition to those of the hematopoietic 
syndrome, impaired immune function being of particular importance [2].  Since ARS 
sub-syndromes overlap, patients faced with the GI syndrome are still highly susceptible 
to hemorrhage and infections due to a depressed immune system.  Decreased intestinal 
epithelial barrier function results in an increased risk of bacterial translocation into the 
blood, and coupled with a diminished ability to combat infection, results in an increased 
incidence of sepsis and death and a marked shift in the mortality curve.      
 
 
Neurological Syndrome 
 
Total body doses above approximately 30 Gy will elicit the neurological (CNS) 
syndrome due primarily to hypotension and cerebral edema.  At CNS syndrome doses, 
cardiovascular damage also occurs and death occurs within hours to days [2].  Symptoms 
include loss of consciousness in addition to all of those experienced in the hematopoietic 
and gastrointestinal syndrome with a more severe and rapid onset. The CNS syndrome is 
the least studied due to the fact that very few accident victims worldwide have 
encountered this extremely high dose.  It must be noted, however, that even at nonlethal 
ARS radiation doses neurological effects may be seen after several days manifested by 
lower response rates [11, 12].  Under the current understanding of the biophysical 
pathways and effects elicited by these very high doses of TBI, it is unlikely that a 
survival advantage could be obtained. 
 
 
Clinical Progression of ARS   
 
Time to Onset.  Symptoms of ARS may be seen as early as 1-2 hours after 
exposure.  Symptoms include vomiting, diarrhea, headache, altered consciousness, fever, 
and hematological changes.  As radiation dose increases, symptoms become more severe 
and appear earlier [2, 8].  There are three phases describing the progression of ARS:  (1) 
Prodromal, (2) Latent phase, and (3) Critical Phase.  The prodromal phase occurs very 
soon after exposure and may include mild to moderate physical symptoms, but is rarely 
lethal.  Following the prodromal phase, there is a latent period lasting a variable amount 
of time, depending on the absorbed dose.  The length of the latent period ranges from 0-
35 days and is inversely related to the radiation dose.  The latent phase is often free from 
manifested symptoms.  The critical phase is defined as the peak of bone marrow 
depression resulting in leucopenia and thrombocytopenia and occurs sooner as the dose 
increases.  Death due to infection and hemorrhage tend to correlate with this nadir [2, 13]. 
 
Hematological Kinetics.  The myelosupression resulting from TBI is dose-
dependent [13].  Irreversible injury shows initial granulocytosis and progressive decline 
of cell counts to nadir around day 6.  The initial granulocytosis is due to rapid 
mobilization of granulocytes from reserve pools, and the approximate 4 day maturation 
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time of granulocytes in the bone marrow.  Assuming irreversible injury (all pre-cursor 
cells in the bone marrow have been destroyed), once these cells have appeared in the 
blood, the decline occurs rapidly. A normal lymphocyte count in an adult is 1.4-3.9 x 
104
 
/L [14].  Lymphocytes show progressive decline and nadir within 48 hours.  This 
rapid decline is not a result of radiation sensitivity of the lymphocyte, but rather an 
impaired ability to re-circulate.  Therefore, lymphocyte decline is not necessarily 
indicative of degree of bone marrow damage, however, a 50% decline at 24 hours after 
exposure may indicate a lethal radiation dose has been absorbed (Figure 1-4) [14].  
Platelets show progressive decline over the first 10 days with nadir at day 10.  This linear 
decline in platelets over 10 days is reflective of the survival time of circulating platelets 
and indicative of all megakaryocyte precursors in the bone marrow having been 
destroyed.  Reversible injury shows moderate initial granulocytosis and decline between 
days 4-10, an abortive recovery and nadir at days 20-30.  Lymphocytes show nadir within 
2 days, and slow recovery (over ~ 25 days).  Platelets show an initial 10 day shoulder, 
and then decline and nadir near day 20 that lasts through day 30 [3, 8, 9]. 
Manifestations.  Symptoms of moderate Hem-ARS is due to exposure to levels 
of ionizing radiation around 3-4 Gray.  Severe Hem-ARS is seen at ionizing radiation 
doses from 4 Gy [2, 4].  While ARS can affect many organ systems (e.g., dermal, 
cardiovascular), acute lethality generally results from destruction of the hematopoietic 
system (“Hem-ARS”) or related complications (e.g. sepsis).   
 
 
RADIATION INJURY 
 
Ionizing radiation (IR) may consist of particulate or electromagnetic radiation.  
Simulation of ARS for drug development and research purposes likely involves 
electromagnetic radiation.  IR comes from the portion of the electromagnetic spectrum 
characterized by high frequency and short wavelength.  Biological damage results from 
the absorption and deposition of energy in cells and tissues.  This energy deposition 
occurs non-homogenously and therefore requires much less total energy to cause damage 
than non-ionizing radiation [15].  Damage induced by ionizing radiation encompasses 
two primary categories:  initial damage and bystander damage.  The importance of 
understanding the effect a novel radiomitigant has on mitigating the bystander effect may 
help to expand the treatment window that the compound may be first administered and 
retain efficacy. 
 
 
Initial Effect 
 
The two causes of initial damage from directly irradiating cells are the charged 
particles that directly interact with cellular structures (direct action), and free radical 
generation which induces double strand breaks and oxidative stress (indirect action). 
The energy deposited in a cell when it is irradiated is primarily absorbed by water leading 
to the nearly instantaneous production of radical intermediates.  These intermediates are 
then free to react with other cellular structures. 
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Figure 1-4  Characteristic Lymphocyte Kinetics after Varying Radiation Doses
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Bystander Effect 
 
Signals are produced by the initially damaged cells and are transferred through 
media and to a lesser extent through gap junctions.  The damage caused to unirradiated 
cells through these signals is a phenomenon known as bystander or non-targeted effects.  
Generally, the term ‘Bystander Effect’ is used in the setting of non-therapeutic use of 
radiation such as in an accident or nuclear attack because there is no intended ‘target’ for 
the radiation. 
 
 
Mechanisms of Radiation-Induced Cell Death 
    
 Apoptosis.    The process of programmed cell death known as apoptosis plays a 
crucial role in the biological effects caused by ARS.  It is involved in both normal 
cellular regulations in organs and in disease states.  Organs which demonstrate high 
proliferative and hematopoietic activity have a higher baseline level of apoptosis.  
Apoptosis is characterized by specific cellular changes including chromatin condensation, 
mitochondrial swelling, DNA cleavage, and loss of membrane integrity.  Apoptosis may 
proceed via a Caspase-8 or Caspase-9 dependent pathway; however they converge during 
execution initiated by cleavage of Caspase-3 (Figure 1-5) [16]. 
   
Intrinsic.  Apoptotic cell death which is initiated from within the cell results in 
death via the intrinsic pathway, also known as mitochondrial or Caspase-9 dependent cell 
death.   It has recently been reported that death from Hem-ARS requires intrinsic 
apoptosis [17].     
   
Extrinsic.  Apoptotic cell death which is initiated outside the cell results in death 
via the extrinsic pathway, also known as Caspase-8 dependent cell death or death 
receptor pathway.  Extrinsic apoptosis occurs without mitochondrial involvement.   
 
Mitotic Cell Death.  The process known as mitotic cell death or mitotic 
catastrophe results when a mitotic arrest occurs during which intrinsic apoptotic pathway 
hallmarks become activated.    
 
 
COMBINED INJURY 
 
In the aftermath of a nuclear detonation it is feasible that there would be 
combination injuries involving damage from both the radiation coupled with wounds of 
varying severity.  TBI in combination with vascular, dermal, or muscular injuries will 
decrease survival.  Due to the importance of considering realistic scenarios, a compound 
being considered for an ARS indication must contemplate efficacy in a combined injury 
setting. 
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Figure 1-5  Simplified Apoptotic Pathway
  
. 
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BIOMARKERS 
 
The use of biomarkers in the setting of ARS has been primarily investigated for 
use in dosimetry [18, 19].  Renewed interest in biomarkers for use as pharmacodynamic 
or surrogate endpoint markers emerges in light of the quest for development of 
pharmaceutical treatments for ARS.   
 
 
Circulating Blood Counts 
 
The most widely used biomarker is complete blood counts (CBC).  CBC analysis 
has been used both to indicate dosimetry and therapeutic response [13, 20-22].  
Specifically, the kinetics of circulating blood cells (granulocytes, lymphocytes, and 
platelets) are used to retrospectively estimate radiation dose, extent of hematopoietic 
injury, and likelihood of spontaneous recovery without treatment [9, 23].  CBC analysis 
is very useful, in indicating the extent of damage, however, due to reports that function 
may be impaired despite increased circulating numbers, CBC counts may not be the best 
way to evaluate recovery [7, 22].   
 
 
Amylase 
 
Serum amylase is used as an indicator of damage to the parotid gland by radiation 
[24, 25].  Serum amylase is the result of interphase cell death of serous salivary cells.  It 
must be measured within 0.5-2 days of the initial radiation event in order to correlate 
elevated levels with exposure [14, 24].  In non-human primates mates, significant inter-
subject variability was observed when measuring serum amylase, with somewhat less 
variability in plasma amylase [14].  Serum amylase returns to baseline within a few days 
after radiation exposure, thereby limiting the use of amylase to predict efficacy of 
countermeasures. 
 
 
Flt3-Ligand 
 
The Flt3-ligand (FL) is a 34 kDa cytokine which works synergistically with other 
hematopoietic growth factors (HGF) to induce the proliferation of pluripotent 
hematopoietic progenitor and stem cells [19, 26].  The Flt3-ligand has been used in a 
clinical setting as late as day 20 post TBI exposure as a measure of the extent of 
hematopoietic exposure and correlates with hematopoietic nadir [27].    
 
 
Citrulline     
 
Citrulline is an amino acid produced by enterocytes and used as an indicator of 
gastrointestinal damage [27].  It may be measured in plasma by chromatographic 
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methods, and has been shown to reflect actual mucosal damage rather than absolute 
radiation dose.   
 
 
AVAILABLE INTERVENTIONS 
 
Although there is a single product, amifostine, approved by the FDA for 
administration prior to radiation, there are currently no known approved drugs that can be 
administered after
 
 TBI exposure to enhance survival due to ARS.   
 
Radioprotectants 
 
Prophylactic potassium iodide administration to protect the thyroid from exposure 
to excess 132
 
I, Chelating agents such as diethylene triamine pentaacetic acid (“DTPA”) to 
decrease exposure by binding and promoting urinary excretion and similarly, laxatives, 
and absorbing agents such as Prussian blue to limit GI absorption or high oral doses of 
calcium to compete with intestinal absorption of milk contaminated with strontium90.  
Amifostine is a thiol compound under investigation as a radioprotectant.  It has been used 
to prevent mucositis caused by head-and-neck irradiation but must be administered in 
advance of radiation exposure.  Furthermore, its side effects (hypotension) would limit its 
use in emergency first responders [28]. 
 
Biologicals 
 
Growth factors are present abundantly in the circulation of people suffering from 
radiation injury [9].  The use of biological products such as G-CSF for the treatment of 
ARS is controversial.  Agents that have not been approved by the FDA as radiomitigants 
but are under investigation as regenerators include cytokines such as granulocyte colony 
stimulating factor (“G-CSF”) and granulocyte-macrophage colony stimulating factor 
(“GM-CSF”).  Both must be given parenterally in a sophisticated medical setting as with 
bone marrow transplant.  Various lipopeptide agonists of Toll-like Receptors (e.g., 
TRL2/TRL6) are under investigation as an aid to bone marrow transplantation.  Other 
TRL agonists are under investigation for treatment of Hem-ARS and oral mucositis 
following head and neck therapeutic irradiation.   
 
 
Supportive Care 
 
The use of supportive care is critical for optimum survival outcome in ARS, 
particularly at low TBI doses.  Supportive care includes administration of antibiotics, 
fluids, blood products, isolation from secondary infections, and regulation of body 
temperature. 
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Bone Marrow Transplant 
 
With regard to Hem-ARS, bone-marrow transplants (BMT) have been used for 
irradiated victims without success [1-3].  27 of the 31 patients that received BMT died.  
The four survivors rejected the transplant and spontaneously repopulated with their own 
stem cells [1, 4].  Furthermore, bone marrow transplants would not be practical after a 
large scale disaster involving large numbers of patients requiring treatment.  
 
 
CENTRAL HYPOTHESIS 
 
The ideal treatment for ARS would be a physically stable compound that could be 
easily and rapidly administered to large numbers of people exposed to a range of 
radiation doses.  The treatment should retain effectiveness when administered as a single 
dose no sooner than 24 hours after exposure. The treatment should result primarily in 
improvement in survival and secondarily in alleviation or improvement in associated 
morbidities. 
 
A drug approved for use in the treatment of ARS must attain approval through the 
path set forth by the so-called “Animal Rule” because ethical considerations prevent pre-
approval efficacy testing in human subjects.  The “Animal Rule” is encompasses four 
primary pillars:  (1) understanding the mechanism of the toxicity of the substance 
(radiation) and its prevention or substantial reduction by the product (2) demonstrating 
the effect in more than one animal species that is expected to react with a response that is 
predictive for humans (3) demonstrating efficacy in the animal study endpoint that is 
clearly related to the desired benefits in humans, and (4) characterizing the 
pharmacokinetics and pharmacodynamics in such a way that allows selection of an 
effective human dose.   
 
Specific aim 1 (Chapter 2) focused on identifying primary endpoints in 
established and novel in vivo radiation models.  In this aim we tested our lead compound, 
KZ-41, for efficacy on our primary endpoint- 30 day mortality.  We also developed an in 
vivo model to evaluate the effect of radiation on vascular injury, specifically clotting 
abnormalities.  We tested the efficacy of KZ-41 in restoring thrombus formation after 
radiation in this novel model. 
 
In specific aim 2 (Chapter 3), we wanted to focus on the pathways involved in 
indirect damage caused by radiation.  Our aim was to develop a model that would allow 
testing of agents administered at least 24 hours after the initial radiation injury.  To this 
end, we developed an in vitro bystander effect model using human U937 cells, and tested 
the effect KZ-41 had on pathways involved in apoptotic cell death.  We also compared 
the effect next-generation radiomitigating compounds to KZ-41 in the bystander effect 
model. 
 
Specific aim 3 (Chapter 4) focused on initial pharmaceutical profiling of next-
generation radiomitigant KZ-157.  We first developed a LC-MS/MS assay to measure 
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KZ-157 and its primary metabolites in biological matrices.  We then measured protein 
binding, susceptibility to P450 metabolism, and characterized the concentration-time 
profile after i.v. and oral administration to rats.       
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CHAPTER 2.  IN VIVO RADIATION INJURY 
 
 
INTRODUCTION 
 
There is growing concern that the potential for nuclear attack is increasing.  Small 
scale attacks could involve hundreds to thousands of people exposed to total body 
irradiation (TBI) [1].  Radiation exposures greater than 1 Gy, involving a significant 
portion of the body and delivered at a relatively high dose rate induces Acute Radiation 
Syndrome (ARS).  Such radiation exposure can be from a nuclear accident (e.g., 
Chernobyl), from a military event (e.g., Hiroshima and Nagasaki), or through a terrorist 
incident.  Victims whose TBI dose ranges from 2-6 Gy, eliciting the response known as 
the hematopoietic syndrome, will be most likely to be saved with treatment.   It is 
estimated that without supportive care (antibiotics and transfusions), a radiation dose of 
approximately 3.5-4.5 Gy will result in death of 50% of persons exposed within 60 days 
[3, 5, 6],  and that nearly all untreated persons exposed to doses greater than 6 Gy will die 
within 30 days of exposure [2].  The primary causes of death of persons suffering from 
Hem-ARS are hemorrhage and infection due to the dose-dependent damage to the 
hematopoietic stem cells.   
 
There is an urgent unmet therapeutic need for radiomitigating (administered at 
least 24 hours after radiation injury) and radioprotecting compounds (administered less 
than 24 hours after radiation injury) which produce an improvement in survival.   
 
Although the endpoint of improving survival seems to be clear-cut, in situations 
such as nuclear accident or attack, there will likely be additional injuries secondary to the 
radiation exposure.  It has been estimated that as many as 60-70% of ARS patients will 
have other injuries, and these patients will have a significantly lower LD50/60
 
, as 
secondary  injury negatively impacted survival [5, 29].  Additional injuries increase the 
probability of introduction of infection that a compromised hematopoietic system cannot 
combat.  Hematopoietic recovery must be attained or the patient will have no chance to 
recover from other injuries [9].  Therefore, hematopoietic support is essential at all 
radiation doses relevant to induce ARS.   
Little is known about the effects of vascular injury in the setting of high doses of 
total body irradiation simulating a nuclear accident or attack.  Total body irradiation 
delivered in large doses, to most or all of the body in a short period of time induces ARS 
and causes widespread effects in the exposed organism.  The hematopoietic syndrome 
occurs even at the lowest doses that cause ARS, at approximately an LD50/30 
 
in mammals 
[30].  The hematopoietic syndrome encompasses two sub-syndromes characterized by 
leucopenia and thrombocytopenia.  Our focus in the combined radiation model is to 
evaluate the initial steps of wound healing in the vasculature primarily early thrombus 
formation, translating to subjects presenting with the hematopoietic syndrome who die 
from hemorrhage caused by thrombocytopenia [30].   
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Radiation injury models are often established where they are routinely 
implemented due to additional variables that must be characterized including type of 
electromagnetic radiation (γ-ray vs. x-ray), source (60Co vs. 137
 
Cs), dose rate, and normal 
bacterial flora found in the local vivarium.  It is nearly impossible in a non-GLP facility 
to directly implement an established model without minor modifications.  Therefore, it is 
of critical importance to clearly outline and account for as many variables as possible 
when designing a radiation model.      
Unique challenges are presented when developing and characterizing a combined 
injury model in addition to those discussed for radiation injury models.  The desire to 
produce the most robust model must be delicately weighed against approaching relevant 
radiation doses and endpoints.  Also, it is widely accepted that excessive handling and 
manipulations cause a shift in both the radiation dose required to cause lethality and the 
time to reach such an endpoint.  This is of particular importance when dealing with 
smaller model types, such as mice.  Special consideration must be taken when choosing 
the timing of both insults, radiation dose used, supportive care required, extent of 
secondary insult, and timing (in relation to injuries) of the endpoint measurement.  All of 
these factors are intimately connected, and changes in one parameter must not be made 
after the model is established without measuring the impact on all other relevant factors. 
  
 
MATERIALS AND METHODS 
 
 
Animals 
 
Animals were purchased from 
 
Jackson Labs (Bar Harbor, ME). Animals were 
maintained under specific pathogen-free conditions with controlled temperature (22° C) 
and humidity (50%) and on 12-hr light/dark cycles.  Animals were allowed a minimum 
acclimation period of 72 hours from time of arrival prior to subjection to any procedure. 
Standard laboratory food and tap water were available ad libitum.  
Survival Study.  Female C57/BL/6 mice at least 12 weeks old were used.  These 
studies were reviewed and approved by the Animal Care and Use Committee of the 
Veterans Hospital, Memphis, TN. 
 
Imaging Study.  Male C57/BL/6 mice weighing 25-30g were used.  These 
studies were reviewed and approved by the Animal Care and Use Committee of the 
University of Tennessee Health Science Center. 
 
 
Irradiation and Treatment 
 
A radioactive cesium 137 (137Cs) source was used for irradiation.  KZ-41 was 
prepared as a solution in 0.9% Sodium Chloride at a concentration of 10 mg per mL.   
KZ-41 was synthesized as previously described in Dr. Duane Miller’s laboratory [5]. 
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Survival Study.  Animals were irradiated at a dose rate of approximately 3 
Gy/minute.  A dose of 6.5 Gy was delivered uniformly to the entire body of each animal.  
Animals were irradiated un-anesthetized in groups of 5 on a rotating platform            
(Figure 2-1).  Treatments were administered as a single dose 25 hours after TBI.  The 
“treatment” group received KZ-41 (100 mg/kg, s.q.), the “vehicle” group received 0.9% 
Sodium Chloride (10 µL per 1 gram body weight, s.q.).  
 
Imaging Study.  Animals were irradiated at a dose rate of approximately 8 
Gy/minute.  A dose of 6 Gy was delivered uniformly to the entire body of each animal.  
Animals were irradiated individually in the upright position on a rotating platform while 
anesthetized (Figure 2-2). Animals were divided into 3 groups for treatment.  Treatment 
began 12 hours after TBI, and continued every 24 hours for the duration of the study.  
The “treatment” group received KZ-41 (100 mg/kg, i.p.), the “vehicle” group received 
0.9% Sodium Chloride (10 µL per 1 gram body weight), and the “sham” group received 
no injection. 
 
 
Murine Survival 
 
After irradiation, and administration of treatement 26 hours after TBI, animals 
were monitored closely.  The number of animals surviving in each group was 
documented for a period of 30 days.    
 
 
Dorsal Window Surgery 
 
Surgery was carried out as described previously [3, 4] with modifications. All 
surgical procedures were carried out aseptically.  After the animal was anesthetized, a 
suitable area of skin on the dorsum was marked for hair removal with a clipper followed 
by use of hair remover lotion. The surgical area was disinfected with alcohol and 
betadine. A thin dorsal skin fold was lifted from the back and sandwiched between two 
titanium plates (Figure 2-3). The titanium plates were firmly fixed with three screws and 
nuts through the holes made in the fold.  The skin was sutured to the top of the plates for 
added stability.  A circular section of the skin on one side of the skin fold along with its 
cutaneous tissue and fascia was incised through the window of the dorsal skinfold 
window chamber (DSFC) assembly to expose the blood vessels and the striated muscle of 
the opposing skin of the dorsal skin fold. Antibiotic ointment containing bacitracin zinc, 
polymyxin B sulfate and neomycin sulfate was applied to the edges of the incised wound 
and a glass window fixed with a snap ring on top of the exposed area inside the DSFC 
(Figure 2-4).  Animals received analgesic every 12 hours for the first 48 hours after 
surgery.  Animals were allowed 3 days to recover after dorsal skin fold chamber fixation 
prior to baseline measurements and radiation.   
 
 
 
 
16 
 
 
 
 
Figure 2-1  Delivering TBI for Survival Study
Unshielded mice were irradiated unanesthetized 5 at a time on a rotating platform.  The 
dose rate was approximately 3 Gy/min and a total dose of 6.5 Gy (LD80/30) was 
delivered. 
. 
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Figure 2-2  Delivering TBI for Imaging Studies. 
  
Window bearing anesthetized mice were irradiated individually on a rotating platform 
without shielding.  The dose rate was approximately 7 Gy/min and a total dose of 6 Gy 
was delivered. 
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Figure 2-3  Dorsal Skinfold Window Apparatus
 
. 
 
 
 
 
 
 
Figure 2-4  Mouse Fixed with DSFC
C57/BL6 mice were surgically fixed with the dorsal window and allowed to recover for 3 
days prior to further manipulation. 
.   
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Intravital Microscopy 
 
Window-bearing animals were anesthetized and received an intra-orbital injection 
of rhodamine 6G (0.4 mg/kg body weight) for leukocyte visualization. All experiments 
were carried out using an industrial grade microscope (Nikon MM-11) with two light 
sources, bright-field (Opti-Quip 75 W xenon) and fluorescent (Nikon 150 W mercury).  
Experiments were viewed on a video monitor and recorded for off-line processing.  The 
video images were analyzed off-line using MetaMorph software (Universal Imaging Co.).  
Rolling and Adhered (stationary for > 30 seconds) leukocytes were quantified and 
recorded.   
 
 
Induction of Vascular Injury 
 
The snap ring and glass window covering the dermal vasculature was removed.  
The tissue was slightly swabbed with sterile cotton tipped applicator.  Immediately prior 
to injury induction animals were injected with Rhodamine 6G so that leukocytes and 
platelets would be visible microscopically. The vascular injury was induced by “nicking” 
a vessel with a sterile 30-gauage needle.  Once the nick was induced, a new cover slip 
was placed over the tissue and secured with a metal snap ring (Figure 2-5).  Animals 
were immediately placed on the imaging platform for intra-vital imaging.   Animals were 
injured (vascular injury) every 24 hours beginning 24 hours after TBI to establish model 
parameters (Figure 2-6). 
 
 
Blood Collection 
 
Window-bearing animals were anesthetized with ketamine/xylazine (87:13, i.p.) 
and blood was collected via cardiac puncture into plasma separator tubes containing 
lithium heparin.  Blood was gently mixed by inversion and immediately placed on ice 
until analysis and processing.  Processed plasma (centrifuged at 10,000 x g 10 min 4° C) 
was aliquoted and stored at -80° C until cytokine/chemokine analysis. 
 
 
CBC Analysis 
 
Complete blood analysis was performed on heparinized whole blood with a 
Beckman Coulter® Ac•T diff™ Analyzer as quickly as possible after collection (< 1 
hour).   
 
 
Cytokine/Chemokine Analysis 
 
Following CBC analysis, blood was processed and stored as described above.  
Cytokine concentrations in the plasma of animals from all groups was analyzed using the 
Luminex platform.   
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Figure 2-5 Low Magnification Image of Dermal Vasculature
Low magnification view of the dermal vasculature following surgical implantation of 
DSFC.  Red arrow indicates an ideal site for injury induction. 
.  
 
 
 
 
 
 
 
Figure 2-6  Imaging Study Timeline
Window implantation occurred on study day 1 with radiation on day 3.  Daily treatments 
began 12 hours after radiation and continued through the end of the study.  Vascular 
injury was induced on study day 6, with imaging immediately following.  A second 
image was collected 24 hours after injury (Study day 7) to evaluate flow restoration. 
.  
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Data Analysis 
 
All data are expressed as mean plus or minus standard deviation. P values of < 
0.05 were considered statistically significant. 
 
 
RESULTS 
 
 
Murine Survival 
 
The primary endpoint of this study was 30-day mortality.  Animals treated with a 
single dose of KZ-41 26 hours after lethal total body irradiation showed an approximate 
40% improvement in survival when compared with vehicle (saline) treated animals 
(Figure 2-7). 
 
 
Clot Formation 
  
The primary endpoint in our imaging model was clot formation.  Initial clot in 
control (unirradiated animals) occurred within 2 minutes of injury (Figure 2-8A), and 
evidence of remodeling could be observed as early as 8 minutes after vascular injury.  
There was no difference in clot formation when vascular injury was induced 24 or 48 
hours after TBI compared to control.  There was no clot formation when vascular injury 
was induced 72 hours after TBI (Figure 2-8B).  96 hours after TBI animals demonstrated 
fragile vasculature and poor window quality which prevented consistent vascular injury 
and analysis (Table 2-1).  Induction of vascular injury 72 hours after TBI was optimal for 
treatment evaluation in this model; therefore, all treatments were evaluated under this 
time scheme.  In untreated animals injured 72 hours after TBI, no clot formed in 5 of 6 
animals measured (Table 2-1).  Animals receiving KZ-41 treatment every 24 hours 
beginning 12 hours after TBI, showed significant improvement in clot formation 
compared with untreated animals (Figure 2-8C), with clots forming in 7 out of the 8 
animals measured (Table 2-1).   
 
 
Flow Restoration 
 
The restoration of flow in the injured vessel both upstream and downstream of the 
injury was analyzed 24 hours after vascular injury.  TBI significantly decreased 
restoration of flow when vascular injury was induced 72 hours after radiation (1/6 TBO 
vs. 5/6 Control animals, Table 2-1).  Three daily treatments with KZ-41 beginning 12 
hours after TBI resulted in flow restoration in 43% of the treated animals (3/7) compared 
with 17% of TBI alone animals, however, this improvement was not statistically 
significant. 
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Figure 2-7  Effect of KZ-41 on Murine 30 Day Survival
KZ-41 (100 mg/kg or Vehicle (normal saline) was administered once 25 hours after lethal 
total body irradiation (LD
.  
80/30
 
). 
n = 24-26 per group  
p < 0.05 
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Figure 2-8  Effect of KZ-41 on Radiation-Induced Clotting Abnormalities
Clot formation after vascular injury in (A) Unirradiated Controls (B) Irradiated + Vehicle 
(Normal Saline), and (C) Irradiated + KZ-41 (100 mg/kg). 
. 
 
 
 
 
 
Table 2-1  Effect of KZ-41 on Clot Formation. 
 
 
 
 
 
 
 
 
Mice were irradiated (6 Gy TBI) and treated (vehicle was normal saline, 100 mg/kg KZ-
41, s.q.) every 24 hours beginning 12 hours post TBI.  Vascular injury was induced 3 
days post TBI and cot formation was immediately assessed.  Flow restoration was 
measured 24 hours following vascular injury.   
 
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05) 
#KZ-41 vs. vehicle treated irradiated mice (p < 0.05)  
 
Group Clot Flow 
 Restoration Restoration 
Unirradiated 5/6 (83%) 5/6 (83%) 
Vehicle 1/6 (17%)* 1/6 (17%)* 
KZ-41 7/8 (88%) 3/7 (43%) # 
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CBC Analysis 
 
Circulating platelet and leukocyte counts were measured in animals receiving TBI 
72 hours prior to vascular injury.  Blood was collected and analyzed at the completion of 
the study (96 hrs post TBI).  There was a significant decrease in both platelet and 
leukocyte numbers in the periphery (Figures 2-9, 2-10).  Animals treated with KZ-41 did 
not have elevated platelet or leukocyte counts compared with untreated animals (Figures 
2-9, 2-10).   
 
 
Cytokine Analysis 
 
Circulating KC and TNF-α concentrations were measured in animals receiving 
TBI 72 hours prior to vascular injury.  Blood was collected and analyzed at the 
completion of the study (96 hrs post TBI).  There was a significant increase in circulating 
KC and TNF-α in animals receiving TBI alone compared to control animals.  There was 
no difference in measured cytokine levels between KZ-41 and untreated animals 
(Figures 2-11, 2-12).   
 
 
DISCUSSION 
 
There is currently no small-molecule approved for administration after exposure 
to radiation doses causing acute radiation syndrome to improve survival.  The primary 
causes of death in individuals suffering from the heme-syndrome of ARS are infection 
and hemorrhage.  These individuals exhibit decreased levels of circulating leukocytes and 
platelets (pancytopenia).  The complications present in patients affected by ARS at the 
lower heme doses are also present and problematic in higher ARS doses (GI and CNS); 
therefore, it is important to have in vivo models in place to evaluate and develop potential 
treatments for all doses of ARS.     
 
We have demonstrated that KZ-41 significantly improves survival when 
administered as late as 26 hours after lethal total body radiation.  KZ-41 is a novel small 
molecule with an attractive biopharmaceutical profile which makes it an ideal drug 
candidate.  Although the survival study met the efficacy endpoint for ARS, we wanted to 
further investigate the mechanisms by which KZ-41 was exerting its effect, particularly 
in the setting of combined vascular injury, while simultaneously addressing an unmet 
need for combined injury models. 
 
The described combined injury model was optimized using 6 Gy Total Body 
Irradiation coupled with vascular injury on day 3 post TBI (Figure 2-6).  Complete blood 
analysis, cytokine measurements, and other parameters may also be studied in the same 
animals as the imaging when coupled with careful interpretation.  Imaging endpoints in 
our study were clot formation and restoration of flow, however, leukocyte activity and 
vessel diameter at the site of injury and in adjacent (irradiated only) vessels as well as 
vessel permeability in uninjured vessels may also be studied.  Under the conditions 
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Figure 2-9  Leukocyte Counts 4 Days post TBI
Blood was collected from window bearing mice on study day 7 and analyzed for 
circulating leukocytes. 
. 
 
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05) 
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Figure 2-10  Platelet Counts 4 Days post TBI
Blood was collected from window bearing mice on study day 7 and was analyzed for 
circulating platelet counts. 
. 
 
*Unirradiated control vs. irradiated vehicle treated mice (p < 0.05) 
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Figure 2-11  KC Concentration 4 Days post TBI
Blood was collected from window bearing mice on study day 7 and was analyzed for 
circulating KC concentration. 
. 
 
*Unirradiated control vs. irradiated vehicle treated (IR) mice (p < 0.05) 
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Figure 2-12  TNF-α Concentration 4 Days post TBI
Blood was collected from window bearing mice on study day 7 and was analyzed for 
circulating TNF-α concentration. 
. 
 
*Unirradiated control vs. irradiated vehicle treated (IR) mice (p < 0.05) 
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described, there was a significant reduction in the formation of a clot immediately 
following vascular injury and restoration of vascular flow in the injured vessel compared 
with unirradiated control animals.  The novel radiomitigant KZ-41 significantly restored 
clot formation, and improved the incidence of flow restoration although not to 
significance when first administered 12 hours following lethal TBI.  The effect of KZ-41 
on clot formation in this model was not related to circulating platelet numbers as 
evidenced to similar platelet counts as untreated irradiated animals.  We hypothesize that 
the effect demonstrated in the imaging model on clot formation is due to platelet 
function, and further analysis is planned to test these hypothesis.    
  
Although this model has proved invaluable in our drug evaluation studies, there 
are limitations that should be considered.  The surgery and subsequent radiation the 
animals receive places them in an extremely fragile state, and in our opinion prevents 
escalation of the dose beyond 6 Gy outside of acute endpoints.  Also due to the physical 
burden of the window, one must evaluate cytokine and chemokine parameters carefully.  
The model that we have developed and described is a unique, versatile model to study 
combined radiation and vascular injury.  This is the first radiation combined injury model 
described which allows investigation of vascular response in the setting of ARS [6].  This 
model may be expanded or condensed based on the specific aims of the project. 
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CHAPTER 3.  IN VITRO MECHANISM 
 
 
INTRODUCTION 
 
Damage induced by ionizing radiation encompasses two primary categories:  
initial damage and bystander damage (or non-targeted effects).  The two causes of initial 
damage from directly irradiating cells is the charged particles that directly interact with 
cellular structures (direct action), and free radical generation which induces double strand 
breaks and oxidative stress (indirect action).  Signals are produced by the damaged cells 
and are transferred through media and to a lesser extent through gap junctions [31].  The 
damage caused to unirradiated cells through these signals is a phenomenon known as the 
bystander effect. 
 
In the setting of ARS understanding the bystander effect is of particular interest 
when discussing the efficacy elicited by a radiomitigant.  By definition, a radiomitigant is 
administered after the radiation event.  Therefore, for a clear understanding of the 
mechanism of action of a radiomitigating compound one must investigate the down-
stream events that occur after the initial “trigger” radiation event.  A recently published 
study investigated the transcriptomes of both directly irradiated and bystander (via media 
transfer) cells and concluded that they are very similar, suggesting a propagation of injury 
phenomenon [32].     
 
Various groups have investigated the bystander effect via directly irradiating a 
single cell(s) by using micro beam radiation and observing the effects on the surrounding 
cells [33].  This experimental setup has primarily focused on the role gap junctions play 
in the bystander effect phenomenon.  Investigations into bystander signaling using mixed 
populations (directly irradiated and unirradiated) of cells as well as multiple cell types 
have been also been conducted.  The important role of death receptor signaling in the 
bystander effect has also been demonstrated using medium transfer experiments [32, 34, 
35]. 
 
Although radiation-induced bystander effects have been demonstrated for a 
variety of biological endpoints, we focus on effector caspase activation as an indicator of 
apoptosis and bystander effect.  Extracellular-initiated apoptosis signaling executes down 
one of two primary pathways.  Mitochondrial independent apoptosis is mediated by 
death-receptor ligand, activation of Caspase-8 then Caspase-3, and ending in apoptosis.  
Mitochondrial dependent apoptosis is mediated by Bax, Bak, Bcl-2, Cytrchrome C 
release, activation of Caspase-9 then Caspase-3, and ending in apoptosis.  The final step 
(Caspase-3 activation) prior to apoptosis is common to both pathways, and is thus an 
attractive surrogate marker for measuring apoptosis. 
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MATERIALS AND METHODS 
 
 
Cell Line 
 
Human monocytic lymphoma cells (U937) stably transfected with a gentamycin 
resistant gene were purchased from ATCC.  Cells were grown in RPMI 1640 media 
supplemented with 10% and 50 µg/mL concentration of gentamycin in a 37° C incubator 
with 5% CO2
 
. 
 
Irradiation 
 
Cells received a dose of 7 Gy from a 137
 
Cs source at a dose rate of approximately 
8 Gy/minute on a rotating plate to ensure uniform exposure.   
 
Treatment 
 
U937 cells were divided into two different treatment groups as discussed below.  
Treatments were dissolved into low serum (1%) medium at a concentration of 100 mM 
and serially diluted to the desired concentration.  All wells were treated in triplicate. 
 
 
Directly Irradiated Cells 
 
Cells were plated in MultiScreenHTS-PCF filter plates (Millipore, Billerica, MA) 
approximately 18 hours prior to irradiation in growth medium containing 1% FBS and 50 
µg/mL at a concentration of 1 x 106 cells per mL.  Cells were incubated under serum 
starved conditions at 37º C with 5% CO2.  All treatments (including vehicle) were 
conducted immediately (approximately 0.5 hours) prior to irradiation.  Treatments were 
dissolved in fresh medium containing 1% FBS and 50 µg/mL gentamycin.  Cells were 
incubated at 37º C with 5% CO2 
 
for various lengths of time following radiation at which 
time cells were analyzed for markers of damage, repair, and apoptosis.     
 
Bystander Effect Cells 
  
Actively growing (bystander) cells were plated in MultiScreenHTS-PCF filter 
plates (Millipore, Billerica, MA) in growth medium at a concentration of 1 x 106 cells per 
mL.  Growth medium was removed via vacuum filtration.  Treatments were dissolved in 
conditioned medium obtained after a 24 hour incubation post irradiation from directly 
irradiated cells.  Conditioned medium +/- treatments were then placed on the actively 
growing unirradiated cells and gently mixed for 1 minute on an orbital plate shaker.  
Cells were incubated at 37º C with 5% CO2 for an additional 24 hours (referred to as 24-
24) at which time cells were analyzed for markers of damage, repair, and apoptosis.     
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Apoptosis 
 
Markers of apoptosis and DNA damage in the samples were measured in cell 
lysate per manufacturer’s protocol using the Beadlyte® 3-Plex Apoptosis Signaling Kit 
and the pH2A.X Beadmate® (Millipore, St. Charles, MO) paired with the Luminex®
 
 
200™ System (Luminex Corporation, Austin, TX).  Controls and samples (50 µL) were 
mixed with 25 µL of bead solution (fluorescent beads conjugated to antibodies for Active 
Caspase-3, GAPDH, Cleaved PARP, and pH2A.X) and incubated overnight at 4° C.  
Wells were washed and beads resuspended in assay buffer.  Biotin-conjugated antibodies 
(anti-Active Caspase-3, GAPDH, Cleaved PARP, and pH2A.X) were added and 
incubated for 1.5 hours.  Streptavidin-Phycoerythrin was added and incubated 30 
minutes.  Unbound reagents were removed and fluorescence intensity reported as the 
median of 100 beads per analyte in each well.  Median Fluorescent Intensity (MFI) 
values are reported as the % change from baseline. 
 
DNA Damage 
 
Millipore pH2A.X Beadmate®  multiplexed with the Millipore Beadlyte® 3-Plex 
Apoptosis Signaling Kit (above) coupled with the Luminex platform. 
 
 
Cell Death 
   
Flow Cytometry was coupled with LIVE/DEAD® Cell Vitality Assay Kit with 
C12-Resazurin and SYTOX® green stain to evaluate metabolically active (live), 
metabolically inactive, and dead cells per manufacturer’s protocol (Molecular Probes). 
Cells in suspension were incubated with 500 nM C12-Resazurin and 10 nM SYTOX 
Green dye at 37° C for 15 minutes in the presence of 5% CO2.   Cell-dye mixtures were 
diluted and kept on ice until analysis by flow cytometry with fluorescence emission at 
539 nm and 575 nm.  C12-Resazurin is reduced to red-fluorescent C12-Resorufin in cells 
that are metabolically active (delineated as live cells from this point forward).  Dead cells 
with compromised plasma membranes will uptake the green-fluorescent nucleic acid 
stain SYTOX® Green dye, emitting green fluorescence.  Metabolically inactive cells 
emit reduced red-fluorescence due to their reduced metabolic rate, but will exclude the 
green dye because they have intact membranes. 
 
 
Death Receptor Ligand Quantification 
 
Media samples were collected and stored at -80° C until analysis with Beadlyte® 
multiplex cytokine analysis kit (Millipore, St. Charles, MO) paired with the Luminex® 
200™ System.  Standards and samples (50 µL) were mixed with 25 µL of bead solution 
and incubated overnight at 4° C.  Wells were washed and beads resuspended in assay 
buffer.  Multi-cytokine biotinylated antibodies were added and incubated for 1.5 hours.  
Streptavidin-Phycoerythrin was added and incubated 30 minutes.  Unbound reagents 
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were removed and fluorescence intensity reported as the median of 75 beads per cytokine 
in each well.  Concentrations were interpolated by fitting fluorescence intensity from 
unknowns to the standard curves. 
 
 
ROS Evaluation 
 
The ROS assay was carried out as previously described with minor 
modifications[36].  Dicholorofluorescindiacetate (DCFH-DA) dye was used for this 
assay. U937 cells were plated at a density of 150,000 cells/well in MultiScreenHTS
 
-PCF 
filter plates (Millipore, Billerica, MA). Plates were then irradiated with a dose of 7 Gy. 
After 24 hours, media was removed via vacuum filtration. Cells were then re-suspended 
in 100uL of 10uM DCFH-DA dye that had been reconstituted in DMSO and diluted in 
PBS. The plate was then covered in aluminum foil and incubated for 5 minutes at 37° C. 
Dye was then removed via vacuum filtration. Cells were reconstituted in 200uL phenol 
red free RPMI. The plate was covered in foil and incubated for 30 minutes on a plate 
shaker at room temperature. Cells were then transferred to a black 96-well plate, and the 
plate was again covered in foil. The plate was incubated 30 minutes further at 37° C. A 
Beckman Coulter DTX 880 Multimode Detector was used to read plate fluorescence with 
excitation and emission settings at 485 and 535 nm respectively. 
 
RESULTS 
 
 
Direct Effect 
 
Apoptosis after Direct Irradiation Exposure.  The effect of a single dose of 
ionizing radiation was evaluated on the U937 cell population over time.  Activated 
Caspase-3 was measured at 1, 4, 24, 36, and 48 hours after IR (ionizing radiation).  A 
bimodal increase was measured 24 and 48 hours after IR (Figure 3-1).  No increase in 
phosphorylated histone 2A (pH2A.X) was observed in the time points that were 
measured (1, 4, 24, 36, and 48 hours) (Figure 3-2).  Significant apoptotic cell death was 
verified 24 hours post IR (Figure 3-3).  The effect of KZ-41 (0.1, 1, 10, and 100 µM) 
treatment 30 minutes prior to IR was investigated at both 24 hours and 48 hours after IR.  
There was no significant effect on active Caspase-3 levels at either 24 or 48 hours after 
IR (Figures 3-4, 3-5).  There was no reduction in apoptotic cell death by KZ-41 24 hours 
after IR, which correlates with the Caspase-3 measurements (Figure 3-6).  
 
Death Receptor Ligand after Direct Irradiation Exposure.  Tumor necrosis factor 
alpha (TNF-α) was measured in the medium as a function of time (1, 4, 24, 36, and 48 
hours) following radiation exposure.  TNF-α levels are below detection at 1 hour after IR 
exposure, however, may be detected as early as 4 hours post exposure.  The maximum 
TNF-α concentration detected in our experiment was observed at 24 hours after exposure 
and was sustained at this elevated level through the last measured time point of 48 hours 
after exposure (Figure 3-7).  KZ-41, when administered 30 minutes prior to irradiation, 
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Figure 3-1 Caspase-3 Activation after 7 Gy IR
U937 cell were irradiated (7 Gy) and Caspase-3 activation was measured using Luminex 
as a function of time as an indicator of apoptotic cell death. 
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Figure 3-2  pH2A.X following 7 Gy IR
U937 cell were irradiated (7 Gy) and DNA double strand breaks were measured as a 
function of time using Luminex. 
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Figure 3-3  Apoptotic Cell Death 24 Hours following 7 Gy IR
U937 cell were irradiated (7 Gy) and stained with propidium iodide 24 hours later.  
Apoptotic cell death was measured by flow cytometry. 
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Figure 3-4  Effect of KZ-41 at 24 Hours on Radiation-Induced Direct Damage
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).  
24 hours after radiation, Caspase-3 was measured by Luminex. 
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Figure 3-5  Effect of KZ-41 at 48 Hours on Radiation-Induced Caspase-3 Activation
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).  
24 hours after radiation, Caspase-3 was measured by Luminex. 
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Figure 3-6  Effect of KZ-41 on Apoptotic Cell Death 24 Hours post Radiation 
Injury
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).  
24 hours after radiation, cells were stained with propidium iodide and apoptotic cell death 
was measured by flow cytometry. 
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dose-dependently (0.1-100 µM) reduced TNF-α concentration in the medium 48 hours 
after irradiation (Figure 3-8).   
 
Reactive Oxygen Species.  Reactive Oxygen Species (ROS) significantly 
increases 24 hours after irradiation, and KZ-41 (1 µM) significantly reduces ROS 
(Figure 3-9).   
 
 
Bystander Effect 
 
 Effect of Irradiation.  The apoptotic effect 24 hours after a single transfer of 
conditioned medium (transferred 24 hours after IR), hereby referred to as 24-24, was 
measured via Caspase-3/7 activity to establish the possibility of a bystander effect in this 
model system.  There is significant accumulation of Caspase-3 24 hours after IR (Figure 
3-10), and degradation of Caspase-3/7 occurs when stored at 37° C compared with -80º C 
for 24 hours (Figure 3-11).  There are differences in total and soluble Caspase-3/7 at 24-
24 (Figures 3-11, 3-12), but not in cellular levels (Figure 3-13). 
 
Effect of KZ-41 and Next Generation Compounds.  KZ-41 caused a dose-
dependent (0.1-100 µM) reduction in Caspase-3/7 in the 24-24 CM experimental setup 
(Figure 3-14).  Next generation compounds (Figure 3-15) were analyzed at 1 µM and 
compared to the efficacy of KZ-41 (Figure 3-16).  KZ-157 demonstrated a significant 
improvement over KZ-41 in reducing Caspase-3/7 levels under this model system at a 1 
µM concentration. 
 
 
DISCUSSION 
 
A single cell type in vitro model where both direct damage and the bystander effect may 
be monitored and used for drug efficacy testing in the setting of radiation injury has been 
presented.  In the U937 cell line, we have shown that a radiation dose of 7 Gy is 
sufficient to induce apoptotic cell death under our experimental conditions.  At 24 hours 
after IR, we were able to measure a significant increase in both Caspase-3 and apoptotic 
cell death (Figures 3-1, 3-3), which is different from a previously published study who 
did not observe significant cell death prior to 30 hours after 7 Gy RI [36].  This group did 
not show the apoptosis data prior to 48 hours but they did mention their findings.  One 
marked difference between the Kim group’s findings and ours is serum starvation.  The 
Kim group did not serum starve prior to radiation, and all of our data is reflective of 
serum starvation (1% FBS) prior to radiation.  This difference is an important one to note 
because serum starvation arrests cells in the G0/G1 phase in the cell cycle [15].  
Approximately 40% of actively growing U937 cells are in S phase which is the most 
radiation resistant phase of the cell cycle [37, 38].  Furthermore, although highly effective 
at promoting survival, we have demonstrated that our lead compound, KZ-41, has no 
effect on Caspase-3 or apoptosis when administered prior to radiation injury (Figures 3-
4, 3-5, 3-6).  Due to the nature of the therapeutic deficiency that we are -α after IR as a 
first step in developing a bystander effect model.  We demonstrated a  
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Figure 3-7  TNF-α Concentration following 7 Gy Radiation Exposure
U937 cells were irradiated (7 Gy).  TNF-α concentration in the medium was measured by 
Luminex as a function of time after irradiation. 
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Figure 3-8  Effect of KZ-41 on TNF-α Production 48 Hours post Radiation
U937 cells were treated with KZ-41 (0-100 µM) and were immediately irradiated (7 Gy).  
48 hours after radiation, TNF-α concentration in the medium was measured by Luminex. 
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Figure 3-9  Effect of KZ-41 on ROS 24 Hours post Radiation
U937 cells were treated with KZ-41 (1 µM) immediately prior to irradiation (7 Gy).  24 
hours after radiation, ROS was measured. 
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Figure 3-10  Caspase-3/7 Activity 24 Hours post CM Transfer
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and placed on unirradiated bystander cells.  24 hours after 
medium transfer, Caspase-3/7 was measured with luminescent plate reader. 
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Figure 3-11  Stability of Caspase-3/7 in Cell Culture Medium
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and either frozen (-80º C) or stored at culture conditions 
(37º C) for 24 hours.  Caspase-3/7 was measured with luminescent plate reader. 
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Figure 3-12  Soluble Caspase-3/7 24 Hours post CM Transfer
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and transferred to unirradiated bystander cells. Cells and 
conditioned medium were allowed to incubate for an additional 24 hours.  Caspase-3/7 
(luminescence) was measured by plate reader in cell-free medium. 
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Figure 3-13  Cellular Caspase-3/7 from Bystander Cells 24 Hours post CM 
Transfer
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and transferred to unirradiated bystander cells with KZ-41 
(0-100 µM).  Cells and conditioned medium was allowed to incubate for an additional 24 
hours.  Caspase-3/7 (luminescence) was measured by plate reader in washed cells. 
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Figure 3-14  Effect of KZ-41 on the Radiation-Induced Bystander Effect
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and transferred to unirradiated bystander cells with KZ-41 
(0-100 µM).  Cells and conditioned medium was allowed to incubate for an additional 24 
hours.  Caspase-3/7 (luminescence) was measured by plate reader. 
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Figure 3-15  Chemical Structure of KZ-157. 
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Figure 3-16  Next-Generation Analog Screening
U937 cells were irradiated (7 Gy) and allowed to incubate for 24 hours.  Medium was 
removed from irradiated cells and transferred to unirradiated bystander cells with 
treatments (KZ-41 and KZ-157 at 1 µM).  Cells and conditioned medium was allowed to 
incubate for an additional 24 hours.  Compounds were screened for their potential to 
reduce Caspase-3/7 compared to KZ-41.  
.   
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time-dependent effect in TNF-α concentration, with a peak beginning at 24 hours after IR 
(Figure 3-7).  We also established that although KZ-41 has no effect on Caspase-3 
activation when administered prior to IR, there is a dose-dependent reduction in TNF-α 
48 hours after IR (Figure 3-8).  KZ-41 was also effective in reducing reactive oxygen 
species levels, another player in the propagation of radiation-induced injury, and possibly 
applicable in the bystander effect [36].  We demonstrated that a bystander effect can be 
elicited in the U937 cell line through soluble factors by a series of conditioned medium 
transfer experiments (Figure 3-10).  We hypothesize that a variety of soluble factors such 
as TNF-α, TRAIL, and Fas ligand are the initiators of this bystander effect, and once the 
bystander cells are exposed to these soluble factors, they initiate the death cascade.  We 
believe that the death cascade progresses through both mitochondrial dependent and 
independent pathways. 
 
Caspase-3/7 is not stable at 37º C, which is the ambient temperature used during 
the experiments, therefore, only a fraction of the Caspase 3/7 measured at the 24-24 time 
point is residual from the conditioned medium transfer (Figure 3-11).  Also, conditioned 
medium from irradiated cells may be collected and stored at -
 
80º C for use in these 
experiments with success; however, there is some loss of potency in inducing Caspase-
3/7 in untreated cells (data not shown).  KZ-41 dose-dependently reduced Caspase-3/7 
levels 24 hours after transfer of conditioned medium taken from cells 24 hours after 
irradiation (Figure 3-14).   
Although we continue to evaluate the efficacy and mechanism of KZ-41 as a 
radiomitigant, we recognize the importance in discovering a potent next-generation 
compound for use in Acute Radiation Syndrome.  We, therefore, conducted a screen of 
next generation KZ-41 analogs in the U937 bystander effect model.  The caffeic acid 
ester of KZ-41 (KZ-157) was shown to be significantly more potent at reducing Caspase-
3/7 in this bystander effect model, compared to KZ-41 alone (Figure 3-16).  Due to 
published reports on the value of antioxidants for use in radioprotection coupled with our 
screening data, we will move forward with pre-clinical pharmaceutical characterization 
of chlorogenic acid analogs, specifically KZ-157 (Figure 3-15).  We hypothesize that 
KZ-157 will have more potent life-saving effect in the in vivo survival studies due to the 
effect of the antioxidant (caffeic acid) portion of the molecule in addition to the proven 
benefit of KZ-41.   
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CHAPTER 4.  PHARMACOKINETIC MODELING OF NEXT GENERATION 
QUINIC ACID ANALOGS 
 
 
INTRODUCTION 
 
 The interest in developing natural products for various indications has rapidly 
grown in recent years.  Inflammation plays a vital role in many disease states, and is 
therefore a fundamental focus for developing natural products.  Central in natural anti-
inflammatory agents are antioxidants.  Radiation injury is one such disease state where 
antioxidants have shown a proven benefit.  The only Food and Drug Administration 
approved drug for the indication of radioprotection is Amifostine and some of its efficacy  
may be attributed to free radical scavenging properties [12].  Amifostine, however, does 
not retain the attractive low toxicity profile of many natural products.    
 
Many antioxidants are naturally occurring in food.  One such antioxidant is 
chlorogenic acid.  There are large quantities of chlorogenic acid in coffee, blueberries, 
chocolate, beer, tea, and many other commonly consumed foods and beverages [39-42].  
Chlorogenic acid is the ester of quinic acid and caffeic acid (CA), and may be broken 
back into its component parts by esterases found in the blood or by enzymatic 
degradation by gut bacteria [40, 43].  Once separated, quinic acid has very low 
bioavailability due to rapid degradation by gut bacteria.  As a result of the low 
bioavailability, the biological activity of chlorogenic acid is attributed to the antioxidant 
potential of caffeic acid.       
 
Our goal was to retain the active portion of chlorogenic acid (caffeic acid) and to 
substitute a known biologically active molecule for the quinic acid portion.  We 
substituted KZ-41 for the QA portion of the molecule because of its proven efficacy in 
our desired setting, Acute Radiation Syndrome.  The result was KZ-157 (Figure 4-1), a 
next generation KZ-41 molecule and chlorogenic acid derivative.   
 
Theoretically, KZ-157 is a pro-drug, however, it is unique in that we hypothesize 
that its primary metabolites (caffeic acid and KZ-41) would also be active.  In order to 
achieve initial pharmaceutical profiling of KZ-157, an analytical method was required so 
that KZ-157 and its metabolites could be measured in a biological matrix.   
 
 
MATERIALS AND METHODS 
 
 
Animals 
 
Double or single cannulated male Sprague-Dawley rats weighing 200-300g 
obtained from Harlan Laboratories (Indianapolis, IN) were used for this study.  The 
locations for the cannula were the jugular vein and/or the femoral vein.  Animals bearing 
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single cannula were used for oral dosing studies, and animals bearing double cannula 
were used for intra venous (I.V.) studies.  All animal experiments were submitted, 
 
 
 
 
 
Figure 4-1  Chemical Structure of Chlorogenic Acid Derivative KZ-157
  
. 
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reviewed, and approved (Protocol # 1629) by the University of Tennessee Animal Care 
and Use Committee.    
 
 
Treatments 
 
A weight based dosing strategy was used in these studies.  A dose of 1 mg/kg KZ-
157 (Figure 4-1) was administered to each animal based on the weight of the subject the 
morning of dosing via the intravenous or oral rout.   The dosing solution was 10 mg/mL, 
therefore a total volume ranging from 0.20 - 0.26 mL was delivered to each animal. 
 
 
PK Sampling Strategy 
 
The blood sampling strategy was the same for both oral and I.V. studies, and was 
as follows:  0, 5, 15, 30, 45, 60, 120, 240, 480, 720, and 1440 minutes after drug 
administration.  Blood was collected from the jugular vein cannula (JVC),  and placed in 
a BD Plasma Separator Microtainer® (BD Biosciences, San Jose, CA) containing lithium 
heparin, gently mixed, and placed on ice until processing JVC was flushed and the 
collected blood volume was replaced with 0.9% Sodium Chloride (NS) following each 
blood collection.   
 
 
Pharmacokinetic Data Analysis 
 
Plasma concentration-time data were analyzed using non-compartmental analysis 
in WinNonlin 5.0.1 (Pharsight Corporation, Mountain View, CA).  The maximum plasma 
concentration (Cmax) observed after oral dosing and the time at which it was observed 
(Tmax) were determined by direct inspection of the individual plasma concentration-time 
profiles.  The terminal half-life (t1/2) was calculated as 0.693 divided by the terminal 
phase rate constant ( λz
 
).   
 
 
 
 
The area under the plasma concentration-time curve from time 0 to infinity 
(AUC0-∞) was calculated by the trapezoidal rule with extrapolation to time infinity. The 
total plasma clearance (CL) was calculated as the dose (D (ng)) divided by the observed 
AUC0-∞
 
.  
 
 
 
 
 
T = 1/2 0.693 
  
λz 
CL = D 
  
AUC0-∞ 
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The fraction of drug absorbed (F) was calculated by dividing the oral AUC0-∞ by 
the intravenous AUC0-∞.  The oral clearance (CLoral
 
) was obtained by dividing the CL by 
F. 
 
 
 
 
 
Volume of distribution (V) was calculated as the dose divided by the product of 
AUC0-∞  λz.  The volume of distribution following the oral dose (Vora
 
l) was determined 
by dividing the volume by F.  
 
 
 
   
 
 
LC-MS/MS Method  
  
Chromatographic separation was carried out using Shimadzu (Columbia, MD) 
LC-10ADvp pumps with a Leap (Carrboro, NC) CTC PAL autosampler HPLC system.  
The analytes were separated with a methanol-2mmol/L ammonium acetate solution 
(65/35, v/v) mobile phase and an Agilent Zorbax C18 column (5µm particle size, 4.6 mm 
x 150 mm).  A flow rate of 0.5 mL/min and an injection volume of 10 µL were used.  The 
total LC run time was 8 minutes.  The column and autosampler were maintained at 
ambient temperature for the duration of the method.  Detection of the analytes and 
internal standard was performed on an API 4000 Q TRAP mass spectrometer equipped 
with an electrospray ion source (Applied Biosystems Sciex, Foster City, CA) operated in 
negative-ion mode. The LC and MS parameters were controlled by Analyst software 
version 5.0.  Multiple reaction monitoring (MRM) scan type was used to monitor the 
transition from precursor to product ion for KZ-157 m/z 394 → 161, CA m/z 179 → 135, 
KZ-41 m/z 232 → 85, and IS m/z 352 → 191.  The dwell time for all analytes was 250 
msec. 
 
 
Standard Samples 
 
Stock solutions of CA, KZ-41, and KZ-157 were prepared in methanol at a 
concentration of 1.0 mg/mL.  The stock solutions were combined and further diluted in 
methanol to make working solutions for standards (20000, 10000, 5000, 2500, 1000, 500, 
and 100 ng/mL).  The IS stock solution was further diluted in methanol to make an IS 
working solution (1500 ng/mL).  Analyte working solutions were then spiked (10X) into 
rat plasma to make calibration standards.  The resulting concentrations of standards and 
F = AUC
 
0-∞, I.V. 
 
AUC0-∞, oral 
CLoral =   CL 
  
F 
V = D 
  
AUC0-∞ * λz 
Voral =   V 
  
F 
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QC samples were 2000, 1000, 500, 250, 100, 50, 25, and 12.5 ng/mL.  Calibration 
standards were prepared fresh daily.  
 
 
Sample Extraction from Plasma 
 
Sample extraction was optimized based on a method previously published [44].  
Plasma aliquots were processed 8 at a time to ensure minimum time between thaw and 
processing.  Aliquots of 100 µL plasma were thawed on ice, and immediately mixed with 
10 µL IS, and 1 mol/L hydrochloric acid and vortexed for one minute.  Ethyl-ether-ethyl 
acetate (1:1, v/v) was added to the sample and vortexed for 10 minutes.  The sample was 
then centrifuged at 10,000 x g for 10 minutes at 4º C.  The supernatant was transferred to 
a clean tube and evaporated to dryness at 35º C under a stream of nitrogen (5 psi).  The 
residue was dissolved in 25 µL methanol, vortexed for 1 minute and centrifuged for 1 
minute at 10,000 x g.  The supernatant was transferred into an autosampler vial where 10 
µL was injected into the LC-MS/MS system for analysis.   
 
 
Rat Microsomal Stability 
 
The role of Phase I metabolism was investigated using pooled rat liver 
microsomes (Cellzdirect, Austin, TX) by monitoring disappearance of parent compound.  
25 µL Compound (50 µM in 0.1 phosphate buffer) was combined with 25µL (10 mg/mL) 
microsomal protein solution and NADPH regenerating solution (1.3 mM NADP+, 3.3 
mM glucose-6-phosphate, 3.3 mM MgCl2, and 1 unit/mL glucose-6-phosphate 
dehydrogenase in pH 7.4 phosphate buffer solution).  Reactions were incubated at 37° C 
for 0, 15, 30, 45, 60, and 90 minutes.  Duplication of this experiment was performed 
simultaneously with the following modifications:  (1) heat inactivated (denatured) 
microsomal protein was used as a negative control and (2) a second known substrate 
(propanalol) was used as a positive control for microsomal activity.  At the end of 
incubation, 10 µL internal standard (KZ-124 1 µg/mL in Methanol) and 10 µL 
Hydrochloric Acid (1M) was added and mixed.  0.8 mL ethyl-ether-ethyl acetate was 
added and the mixture was vortexed on high for 3 minutes.  Samples were centrifuged at 
10,000 rpm at 4° C for 10 minutes.  The supernatant was divided and stored at -
 
80° C.  
Prior to analysis, samples were thawed and evaporated to dryness under a stream of 
nitrogen gas.  The pellet was resuspended in 25 µL methanol and analyzed by LC-
MS/MS.   
 
In Vitro Protein Binding 
 
Protein binding was analyzed using equilibrium dialysis.  RED® (rapid 
equilibrium dialysis) inserts (Pierce Biotechnology Inc, Rockford, IL) coupled with a 
base plate was used for this analysis.  Concentrations ranging from 0.01 to 10 µg/mL 
were tested in rat plasma.  Plasma was mixed (200µL) with the test compound was 
placed in one side of the chamber and 350µL blank isotonic phosphate buffer, pH 7.4 was 
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placed in the other side of the chamber.  The chambers were covered and incubated with 
100 rpm orbital shaking at 37° C for 4-6 hours to allow equilibrium to be achieved.  
Volume of each chamber was checked at the end of the incubation to ensure no volume 
shift occurred.  50µL aliquots of plasma and buffer were separately analyzed to 
determine the drug concentration using LC-MS/MS.  The percent free compound was 
calculated as the ratio of the compound concentration in the buffer and plasma.   
 
 
RESULTS 
 
 
LC-MS/MS Method 
 
Each analyte monitored had a distinct retention time under the established 
conditions.  The retention times for Caffeic Acid, KZ-41, KZ-157 and the internal 
standard were 2.38, 3.27, 3.9, and 4.44 minutes respectively (Figures 4-2, 4-3, 4-4, 4-5).  
The retention times were consistent when measured simultaneously (Figure 4-6). 
 
 
Pharmacokinetics of KZ-157   
 
KZ-157 demonstrates two-compartment pharmacokinetics (Figure 4-7).  Plasma 
concentrations were below the limit of quantification by 2 hours after both intravenous 
and oral administration (Figures 4-7, 4-8).  KZ-157 appeared rapidly in the plasma after 
oral administration with the Cmax being less than 15 minutes in all animals.  The 
pharmacokinetic parameters of each animal dosed via the oral and intravenous routes are 
described in Tables 4-1 and 4-2, respectively.  The volume of distribution was 7066 and 
1909 mL for oral and I.V. respectively.  The half life was very short at 53 minutes for 
oral and 34 minutes for I.V.  There was a large amount of variability, particularly with 
the oral dosing regimen.  The fraction of drug absorbed following oral dosing is low at 
approximately 28% (Table 4-3).             
 
 
Protein Binding of KZ-157 
 
The extent of protein binding of KZ-157 to proteins in rat plasma using 
equilibrium dialysis was determined to be 43.8% bound. 
 
 
Microsomal Stability 
 
KZ-157 is very resistant to metabolism by liver microsomes.  Greater than 70% of 
KZ-157 remains after a 90 minute incubation with liver microsomes. 
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Figure 4-2  Retention Time of Caffeic Acid
The retention time of caffeic acid, a primary metabolite of KZ-157, was determined 
under the specified LC-MS/MS conditions as 2.3 minutes. 
. 
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Figure 4-3  Retention Time of KZ-41
The retention time of KZ-41, a primary metabolite of KZ-157, was determined under the 
specified LC-MS/MS conditions as 3.27 minutes. 
. 
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Figure 4-4  Retention Time of KZ-157. 
The retention time of KZ-157 was determined under the specified LC-MS/MS conditions 
as 3.9 minutes. 
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Figure 4-5  Retention Time of IS
The retention time of the internal standard used in quantification of KZ-157 was 
determined under the specified LC-MS/MS conditions as 4.44 minutes. 
. 
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Figure 4-6  Simultaneous Detection of KZ-157 and Primary Metabolites
 
. 
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Figure 4-7  Concentration-Time Profile of KZ-157 after Intravenous 
Administration
KZ-157 (1mg/kg) was administered intravenously to Sprague-dawley rats (n=4).  Serial 
plasma samples were collected and quantified using LC-MS/MS. 
. 
 
 
 
 
 
 
 
Figure 4-8  Concentration-Time Profile of KZ-157 after Oral Administration
KZ-157 (1mg/kg) was administered orally to Sprague-dawley rats (n=4).  Serial plasma 
samples were collected and quantified using LC-MS/MS. 
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Table 4-1  Pharmacokinetic Data for KZ-157 after Oral Administration. 
 
Subject CL Vssoral AUC oral T F 1/2 
 
(mL/min) (mL) (min*ng/mL) (min)  
5 80 7570 1248 65.37736  
6 159 13636 6306 59.74138  
7 81 6773 12327 57.75  
8 286 286 3491 27.94355  
  
    
 
Mean 152 7066 5843 53 0.28 
Standard Deviation 97 5461 4792 17  
 
 
 
 
Table 4-2  Pharmacokintic Data for KZ-157 after Intravenous Administration. 
 
Subject CL Vss AUC T1/2 
 
(mL/min) (mL) (min*ng/mL) (min) 
1 49 1733 20339 25.29197 
2 50 2910 20127 64.76636 
3 55 1763 18209 23.97924 
4 42 1231 23639 22.42718 
     Mean 49 1909 20579 34 
Standard Deviation 5 710 2254 20 
 
 
 
 
Table 4-3  Mean Pharmacokinetic Parameters of KZ-157 after Oral and IV 
Administration. 
 
Route T1/2 CL   Vss F   
  min mL/min mL   
IV 34 49 1909   
Oral 53 152 7066 0.28 
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DISCUSSION 
 
KZ-157 is a chlorogenic acid derivative and a next-generation analog of KZ-41.  
It was shown to potentially be more potent than its precursor KZ-41 in the in vitro 
bystander effect screen (Figure 3-17).  Our aim was to establish initial pharmaceutical 
profiling of KZ-157.  In order to measure this novel chlorogenic acid derivative, we 
developed an LC-MS/MS method coupled with an extraction method to quantify KZ-157 
and its metabolites in a small biological sample. 
 
Other investigators have reported rapid initial absorption and bimodal peaks 
following a two-compartment model after oral administration of chlorogenic acid [45, 
46].  These groups administered high doses (greater than 200 mg/kg) and were able to 
monitor the primary chlorogenic acid metabolites quinic acid and caffeic acid.  Our initial 
aim was to quantify the KZ-157 metabolites CA and KZ-41 and we acknowledge the 
importance of monitoring them.  The dose we administered to the animals was 
comparatively much lower (1 mg/kg) than those investigators who conducted metabolite 
monitoring, and we feel that with a modest increase in the administered dose we will 
have quantifiable levels of the most common metabolites.  There are also conflicting 
reports of stability in plasma with some suggesting that it is susceptible to esterase 
activity in rat plasma while stable in human plasma.  Our data suggests that KZ-157 is 
susceptible to plasma or whole blood esterase activity in that we can detect CA and KZ-
41 analyte peaks as early as 5 minutes after intravenous administration of KZ-157 (data 
not shown).  Modeling these metabolites is critical due to our hypothesis that the parent 
compound, KZ-157, along with each of the individual metabolites, CA and KZ-41, will 
have biological activity.  It has been reported that chlorogenic acid is poorly absorbed 
from the intestine, and that bioavailability is largely dependent on individual gut 
microflora [40, 47].  Our data suggests that KZ-157 is rapidly absorbed in its native form 
as indicated by its detection 5 minutes following oral administration.      
 
KZ-157 demonstrates two-compartment pharmacokinetics, and rapid absorption 
following oral administration.  The relative resistance to metabolism by liver microsomes 
coupled with the rapid elimination observed suggests high susceptibility to other 
mechanisms of degradation such as esterase activity.  The high variability observed 
during the early time points following oral administration and relatively low 
bioavailability (as demonstrated by a low fraction absorbed following oral 
administration) could be partly due to the mechanism by which this compound is 
absorbed. 
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CHAPTER 5.  SUMMARY 
 
 
 There are currently no FDA approved radiomitigators for the treatment of Acute 
Radiation Syndrome.  An urgent need exists for safe and effective drugs that can be 
administered at least 24 hours after high dose total body irradiation to large numbers of 
patients.  Effects to the hematopoietic system play a central role in the pathogenesis and 
primary causes of morbidity and mortality in patients presenting with ARS.  The 
hallmark of HEM-ARS is hematopoietic dysfunction.  The hematopoietic failure rapidly 
translates to pancytopenia resulting in a decreased ability to fight infection and increased 
bleeding potential.  Death from HEM-ARS is primarily related to sepsis and hemorrhage.  
Hematopoietic effects are present in all patients, regardless of the total absorbed dose, in 
patients affected by ARS due to the presence of overlapping syndromes.  In light of these 
considerations, there is much effort being invested into developing radiomitigating 
compounds specifically for HEM-ARS. 
 
 In our quest to develop a radiomitigating compound for use in HEM-ARS we first 
had to identify a lead compound and demonstrate efficacy in our primary endpoint 
(Specific Aim 1).  Quinic acid derivative KZ-41 was identified as our compound of 
interest and we tested its efficacy in a murine lethal total body irradiation 30 day 
mortality study.  KZ-41 significantly improved survival when administered 25 hours after 
lethal (LD80/30
 
) total body irradiation.  Armed with this information, we sought to learn 
more about the efficacy of KZ-41, particularly in the setting of preventing radiation-
induced abnormalities in thrombus formation. 
 There are few established animal models to study the effects of ARS eliciting 
doses of radiation and potential mitigation by a compound of interest.  Therefore, we 
developed a live animal imaging model to study the effects of vascular injury in the 
setting of high dose TBI (HEM-ARS doses).  We identified our primary endpoint as 
thrombus formation, and optimized the time after irradiation to maximize the difference 
in thrombus formation.  We correlated thrombus formation with circulating platelet 
numbers as a secondary endpoint.  We then tested the radiomitigating (12 hours after 
TBI) efficacy of KZ-41 on radiation-induced abnormalities in thrombus formation.  KZ-
41 significantly increased the probability of thrombus formation after irradiation without 
affecting the circulating platelet numbers.  With this second piece of efficacy data, we 
focused our aim on the mechanism of action of KZ-41. 
 
 To investigate the mechanism of action of the radiomitigating effects of KZ-41 
(Specific Aim 2) we chose to develop an in vitro model in human U937 cells.  We chose 
this monocyte-like cell line because of published reports concluding that death from 
HEM-ARS requires mitochondrial dependent apoptosis in hematopoietic cells.  Because 
we were developing radiomitigating compounds, we believed that we required a model 
that allowed us to investigate indirect or bystander effects.  We demonstrated that a 
bystander effect can be elicited in the U937 cell line through soluble factors by a series of 
conditioned medium transfer experiments, and that KZ-41 dose-dependently reduces 
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Caspse-3/7 activation which is partly due to inhibition of Caspase-8.  Although we are 
making progress towards the mechanism of action of KZ-41, further studies are required. 
 
In an effort to improve upon our existing lead compound, KZ-41, we were 
interested in incorporating the proven efficacy of antioxidants in radiation injury 
(Specific Aim 3).  Our goal was to retain the active portion of chlorogenic acid (caffeic 
acid) and to substitute a known biologically active molecule for the quinic acid portion.  
We substituted KZ-41 for the QA portion of the molecule because of its proven efficacy 
in our desired setting, Acute Radiation Syndrome.  The result was KZ-157 a next 
generation KZ-41 molecule and chlorogenic acid derivative.  We investigated the initial 
pharmacokinetic parameters of KZ-157 both in vivo and in vitro.  We first developed an 
LC-MS/MS method that enabled us to quantify KZ-157 and its primary metabolites in 
biological matrices.  We then administered KZ-157 to rats both intravenously and orally 
to characterize the pharmacokinetics, and evaluated plasma protein binding and stability 
in the presence of liver microsomes.  KZ-157 demonstrates two-compartment 
pharmacokinetics with a rapid absorption and a low bioavailability following oral 
administration and is rapidly eliminated. 
 
 In summary, we have identified and demonstrated radiomitigating efficacy of  
novel radiomitigant KZ-41 in multiple animal models.  We are beginning to understand 
the mechanism of action of its radiomitigating effects via the in vitro assay that we 
developed.  The in vitro model that we have developed may also be used to screen for 
next-generation radiomitigating compounds.   
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